Rapidly progressive squamous cell lung cancer with MET exon 14 skipping mutation metastasized to atypical bone sites – a case report | Zendy

Kengo Nishino | Zendy; Sou Hattori | Zendy; Yukiko Kodama | Zendy; Yuika Sasatani | Zendy; Hiroaki Satoh | Zendy

Open Access

Rapidly progressive squamous cell lung cancer with MET exon 14 skipping mutation metastasized to atypical bone sites – a case report

Author(s) -

Kengo Nishino,

Sou Hattori,

Yukiko Kodama,

Yuika Sasatani,

Hiroaki Satoh

Publication year - 2022

Publication title -

klinicka onkologie

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.204

H-Index - 13

eISSN - 1802-5307

pISSN - 0862-495X

DOI - 10.48095/ccko202272

Subject(s) - medicine , lung cancer , exon , exon skipping , pathology , oncology , biology , gene , biochemistry , alternative splicing

The mesenchymal-epithelial transition factor (MET) exon 14 skipping mutation has recently emerged as a driver gene in non-small cell lung cancer (NSCLC) in clinical practice. Clinical trials of several MET inhibitors have shown the effectiveness of MET inhibitors in NSCLC patients with MET exon 14 skipping mutation. To the best of our knowledge, however, there was no patient with sole MET exon 14 skipping mutation who progressed rapidly and had a poor prognosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research